1. Home
  2. LFMD vs EDIT Comparison

LFMD vs EDIT Comparison

Compare LFMD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LifeMD Inc.

LFMD

LifeMD Inc.

HOLD

Current Price

$4.06

Market Cap

190.9M

Sector

Health Care

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$3.49

Market Cap

206.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LFMD
EDIT
Founded
1994
2013
Country
United States
United States
Employees
384
N/A
Industry
Medical/Nursing Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
190.9M
206.0M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
LFMD
EDIT
Price
$4.06
$3.49
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
6
Target Price
$9.14
$4.92
AVG Volume (30 Days)
910.9K
1.5M
Earning Date
05-05-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
37.50
EPS
N/A
N/A
Revenue
N/A
$31,937,000.00
Revenue This Year
$17.52
N/A
Revenue Next Year
$18.73
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
132.64
52 Week Low
$2.60
$1.23
52 Week High
$15.34
$4.54

Technical Indicators

Market Signals
Indicator
LFMD
EDIT
Relative Strength Index (RSI) 61.04 79.31
Support Level $3.39 $3.32
Resistance Level $4.19 $3.58
Average True Range (ATR) 0.29 0.23
MACD 0.03 0.08
Stochastic Oscillator 77.94 92.04

Price Performance

Historical Comparison
LFMD
EDIT

About LFMD LifeMD Inc.

LifeMD Inc is a patient-centric, direct-to-patient healthcare company providing a high-quality, cost-effective, and convenient way for patients to access virtual medical care and pharmacy services. The Company's portfolio of brands within continuing operations is now managed as a single operating segment, Telehealth. Telehealth platform integrates core capabilities, includes: A nationwide pharmacy network, A wholly-owned commercial pharmacy, A fully integrated patient care center, A direct-to-patient marketing infrastructure for acquisition and retention, and AI-enabled clinical and operational technologies.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: